Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Plasma Cell Disorders

Comparison of upfront tandem autologous–allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma

Bone Marrow Transplantation volume 50, pages 802–807 (2015)Cite this article

Subjects

Abstract

We performed a retrospective analysis of the European Group for Blood and Marrow Transplantation database comparing the outcomes of multiple myeloma patients who received tandem autologous followed by allogeneic PSCT (auto–allo) with the outcomes of patients who underwent a reduced intensity conditioning allograft (early RIC) without prior autologous transplant. From 1996 to 2013, we identified a total of 690 patients: 517 patients were planned to receive auto–allo and 173 received an early RIC allograft without prior autologous transplant. With a median follow-up of 93 months, 5-year PFS survival was significantly better in the auto–allo group, 34% compared with 22% in the early RIC group (P<0.001). OS was also significantly improved in the auto–allo group with a 5-year rate of 59% vs 42% in the early RIC group (P=0.001). The non-relapse mortality rate was lower in the auto–allo group than in the early RIC group, with 1- and 3-year rates of 8% and 13% vs 20% and 28%, respectively (P<0.001). The relapse/progression rate was similar in the two groups, with 5-year rates of 50% for auto–allo and 46% for early RIC (P=0.42). These data suggest that planned tandem autologous allograft can improve overall survival compared with upfront RIC allograft alone in patients with multiple myeloma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447–3454.

    Article  CAS  Google Scholar 

  2. Kroger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755–760.

    Article  CAS  Google Scholar 

  3. Moreau P, Garban F, Attal M, Michallet M, Marit G, Hulin C et al. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood 2008; 112: 3914–3915.

    Article  CAS  Google Scholar 

  4. Rosinol L, Perez-Simon JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008; 112: 3591–3593.

    Article  CAS  Google Scholar 

  5. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356: 1110–1120.

    Article  CAS  Google Scholar 

  6. Gahrton G, Iacobelli S, Bjorkstrand B, Hegenbart U, Gruber A, Greinix H et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood 2013; 121: 5055–5063.

    Article  CAS  Google Scholar 

  7. Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E 3rd et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011; 12: 1195–1203.

    Article  Google Scholar 

  8. Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood 2012; 119: 6219–6225.

    Article  CAS  Google Scholar 

  9. Knop S, Liebisch P, Hebart H, Holler E, Engelhardt M, Bargou RC et al. Allogeneic stem cell transplant versus tandem high-dose melphalan for front-line treatment of deletion 13q14 Myeloma - an interim analysis of the German DSMM V trial. ASH Annu Meeting Abstr 2009; 114: 51.

    Google Scholar 

  10. Giaccone L, Storer B, Patriarca F, Rotta M, Sorasio R, Allione B et al. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood 2011; 117: 6721–6727.

    Article  CAS  Google Scholar 

  11. Crawley C, Iacobelli S, Bjorkstrand B, Apperley JF, Niederwieser D, Gahrton G . Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007; 109: 3588–3594.

    Article  CAS  Google Scholar 

  12. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123.

    Article  CAS  Google Scholar 

  13. Sahebi F, Garderet L, Iacobelli S, Biezen AV, Gahrton G, Kroger N et al. A comparison of two different reduced intensity conditioning (RIC) allograft strategies in patients with multiple myeloma. An EBMT analysis. ASH Annu Meeting Abstr 2010; 116: 3512.

    Google Scholar 

  14. Lokhorst H, Einsele H, Vesole D, Bruno B, San Miguel J, Perez-Simon JA et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol 2010; 28: 4521–4530.

    Article  Google Scholar 

  15. Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005; 105: 4532–4539.

    Article  CAS  Google Scholar 

  16. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628–1633.

    Article  Google Scholar 

  17. Ringden O, Shrestha S, da Silva GT, Zhang MJ, Dispenzieri A, Remberger M et al. Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. Bone Marrow Transplant 2012; 47: 831–837.

    Article  CAS  Google Scholar 

  18. El-Cheikh J, Crocchiolo R, Furst S, Stoppa AM, Ladaique P, Faucher C et al. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma. Am J Hematol 2013; 88: 370–374.

    Article  CAS  Google Scholar 

  19. Danylesko I, Shimoni A, Nagler A . Allogeneic stem cell transplantation and targeted immunotherapy for multiple myeloma. Clin Lymphoma Myeloma Leuk 2013; 13: S330–S348.

    Article  Google Scholar 

  20. Sahebi F, Shen Y, Thomas SH, Rincon A, Murata-Collins J, Palmer J et al. Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up study. Br J Haematol 2013; 160: 199–206.

    Article  CAS  Google Scholar 

  21. Rotta M, Storer BE, Sahebi F, Shizuru JA, Bruno B, Lange T et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood 2009; 113: 3383–3391.

    Article  CAS  Google Scholar 

  22. Vekemans MC, Michaux L, Van Den Neste E, Ferrant A . Long-term survival after allogeneic stem cell transplantation for advanced stage multiple myeloma. Br J Haematol 2014; 166: 616–618.

    Article  Google Scholar 

Download references

Acknowledgements

We thank all participating EBMT institutions and transplant coordinators and data managers. This study was funded by the European Society for Blood and Marrow Transplantation (EBMT) Chronic Malignancies Working Party.

Author information

Author notes

  1. N KrÖger and L Garderet: These two authors contributed equally and shared senior co-authorship.

Authors and Affiliations

  1. City of Hope, Duarte, CA, USA

    F Sahebi & S H Thomas

  2. Southern California Kaiser Permanente, Los Angeles, CA, USA

    F Sahebi

  3. Università Tor Vergata, Roma, Italy

    S Iacobelli

  4. EBMT, University Medical Center, Leiden, Netherlands

    A V Biezen & A Henseler

  5. Helsinki University Central Hospital, Helsinki, Finland

    L Volin

  6. University Hospital, Heidelberg, Germany

    P Dreger

  7. Hôpital E. Herriot, Lyon, France

    M Michallet

  8. Karolinska University Hospital Huddinge, Stockholm, Sweden

    P T Ljungman & G Gahrton

  9. Radboud University Medical Centre, Nijmegen, Netherlands

    T de Witte & N P M Schaap

  10. Hospital Universitario, Salamanca, Spain

    L López-Corral

  11. Cliniques Universitaires Saint-Luc, Brussels, Belgium

    X Poire

  12. University Hospital, Basel, Switzerland

    J Passweg

  13. Centre Pierre et Marie Curie, Alger, Algeria

    R-M Hamljadi

  14. University Hospital Heidelberg, Heidelberg, Germany

    S Schonland

  15. Queens University of Belfast, Belfast, Northern Ireland

    C Morris

  16. University Medical Center, Hamburg, Germany

    N KrÖger

  17. Hôpital Saint Antoine, Paris, France

    L Garderet

Authors
  1. F Sahebi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Iacobelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A V Biezen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Volin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Dreger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Michallet
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P T Ljungman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T de Witte
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A Henseler
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. N P M Schaap
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. L López-Corral
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. X Poire
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J Passweg
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. R-M Hamljadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. S H Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. S Schonland
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. G Gahrton
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. C Morris
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. N KrÖger
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. L Garderet
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the Plasma Cell Disorders Subcommittee of the European Society for Blood and Marrow Transplantation (EBMT) Chronic Malignancies Working Party

Corresponding author

Correspondence to F Sahebi.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sahebi, F., Iacobelli, S., Biezen, A. et al. Comparison of upfront tandem autologous–allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma. Bone Marrow Transplant 50, 802–807 (2015). https://doi.org/10.1038/bmt.2015.45

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.45

This article is cited by

Search

Advanced search

Quick links